Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose ScheduleCompleted
NCT02824198Phase 2Updated Mar 24, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue Fever · Dengue Hemorrhagic Fever
Singapore
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic TherapyCompleted
NCT01499095Phase 3Updated Mar 23, 2022
Sponsor: Sanofi
Type 2 Diabetes Mellitus
United States, Canada, Chile, Finland, France +8 more
Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase DeficiencyCompleted
NCT02292654Phase 1, Phase 2Updated Mar 23, 2022
Sponsor: Genzyme, a Sanofi Company
Sphingomyelin Lipidosis
United States, Brazil, France, Germany, Italy +1 more
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy SubjectsCompleted
NCT02587520Phase 1, Phase 2Updated Mar 23, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Tetanus · Diphtheria · Pertussis · Whooping Cough
United States
Safety and Efficacy of Isatuximab in Lymphoblastic LeukemiaTerminated
NCT02999633Phase 2Updated Mar 21, 2022
Sponsor: Sanofi
T-cell Type Acute Leukemia-Precursor · T-lymphoblastic Lymphoma/Leukaemia
United States, Finland, France, Hungary, Italy +2 more
Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South AmericaCompleted
NCT01187433Phase 2Updated Mar 21, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue · Dengue Hemorrhagic Fever
Brazil
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin AmericaCompleted
NCT01374516Phase 3Updated Mar 21, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue Fever · Dengue Hemorrhagic Fever · Dengue
Brazil, Colombia, Honduras, Mexico, Puerto Rico
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic SclerosisCompleted
NCT02921971Phase 2Updated Mar 21, 2022
Sponsor: Sanofi
Systemic Sclerosis
United States, Argentina, Belgium, Estonia, France +8 more
Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum MalariaCompleted
NCT03660839Phase 2Updated Mar 21, 2022
Sponsor: Sanofi
Plasmodium Falciparum Infection
Benin, Burkina Faso, Gabon, Kenya, Uganda
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in AsiaCompleted
NCT01373281Phase 3Updated Mar 21, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue · Dengue Fever · Dengue Hemorrhagic Fever
Indonesia, Malaysia, Philippines, Thailand, Vietnam
Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in SingaporeCompleted
NCT00880893Phase 2Updated Mar 21, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue Fever · Dengue Hemorrhagic Fever · Dengue Virus · Dengue Diseases
Singapore
The Intensively Follow-up Examinations for Asymptomatic MPS I Infants in TaiwanUnknown
NCT04958070N/AUpdated Mar 17, 2022
Sponsor: Mackay Memorial Hospital
MPS I
Taiwan
Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone TherapyCompleted
NCT00589420Phase 2Updated Feb 17, 2022
Sponsor: Abramson Cancer Center at Penn Medicine
Prostate Cancer
United States
Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple SclerosisCompleted
NCT03135249Phase 4Updated Feb 15, 2022
Sponsor: University of Texas Southwestern Medical Center
Multiple Sclerosis (MS)
United States
COMBACTE-CDI Understanding the Burden of C. Difficile InfectionCompleted
NCT03503474N/AUpdated Feb 9, 2022
Sponsor: University of Leeds
Clostridium Difficile Infection
United Kingdom
To Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus ReproterolCompleted
NCT00777348Phase 2Updated Feb 7, 2022
Sponsor: MEDA Pharma GmbH & Co. KG
Asthma, Exercise-Induced
Germany
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy TreatmentCompleted
NCT00210249N/AUpdated Feb 4, 2022
Sponsor: Institut Bergonié
Lymphoma · Digestive System Diseases · Ovarian Diseases · Pulmonary Disease
France
Dupilumab in Chronic Spontaneous UrticariaCompleted
NCT03749135Phase 2Updated Feb 2, 2022
Sponsor: Charite University, Berlin, Germany
Chronic Spontaneous Urticaria · Recurrent Angioedema
Germany
PCa Patients Managed With ADT to Examine the Effect of Nutritional Guidance and Aerobic/Resistance Fitness TrainingCompleted
NCT04057859N/AUpdated Jan 24, 2022
Sponsor: CMX Research
Cancer of the Prostate
Canada
Broadening Our Understanding of Early Versus Late Influenza Vaccine EffectivenessCompleted
NCT04570904N/AUpdated Jan 19, 2022
Sponsor: University of Leicester
Influenza · Influenza -Like Illness
United Kingdom
Measuring Active Microglia in Progressive Multiple SclerosisCompleted
NCT02207075N/AUpdated Jan 18, 2022
Sponsor: Weill Medical College of Cornell University
Secondary Progressive Multiple Sclerosis
United States
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and ExerciseCompleted
NCT03353350Phase 3Updated Jan 18, 2022
Sponsor: Hanmi Pharmaceutical Company Limited
Type 2 Diabetes Mellitus
United States, Germany, Poland, Ukraine, United Kingdom
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate CancerCompleted
NCT00116142Phase 3Updated Jan 11, 2022
Sponsor: Dana-Farber Cancer Institute
Prostate Cancer
United States
Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)Completed
NCT01186640Phase 2Updated Jan 5, 2022
Sponsor: German CLL Study Group
T-cell-prolymphocytic Leukemia
Germany
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)Completed
NCT01471444Phase 3Updated Dec 16, 2021
Sponsor: M.D. Anderson Cancer Center
Disorder Related to Bone Marrow Transplantation · Leukemia · Transplantation Infection
United States

Previous page Next page